Pfizer, which set out to strengthen its business last year by acquiring rival drug maker Wyeth, said today its fourth quarter sales ballooned by 34 percent. Wyeth’s legacy products, such as the ...

Vaccine maker Wyeth-Ayerst Laboraties agreed to pay a $30-million fine for repeatedly violating federal drug-quality rules at two of its East Coast manufacturing plants, including a flu-shot ...

Hefty charges and a higher tax rate, both related to the $68 billion purchase of Wyeth, dragged the drugmaker's profit down 70 percent, the company said Tuesday.

Federal preemption arguments failed in October to prevent a Nevada jury from awarding three women $134.5 million in their suit against Wyeth over its hormone replacement products Premarin and Prempro ...

American Home Products Corp. is changing its name to Wyeth after 76 years, to reflect the company's focus on research-based pharmaceutical products.

Pfizer employees and investors were probably equally frustrated by yesterday's conference call. Management said it had axed 11,200 jobs at the company and planned to announce more layoffs this ...

Buying Wyeth for $68 billion moves Pfizer back into the over-the-counter consumer-health products market, a business the pharmaceutical giant exited in late 2006.

Pfizer Inc. is buying rival drugmaker Wyeth in a $68 billion deal that will increase its revenue by 50 percent, solidify its No. 1 rank in the troubled industry and transform it from a pure ...

Pfizer's earnings rose 9.5% as the company's revenue was again boosted by its acquisition of Wyeth while sales of its flagship drugs rose.

PREMIUM PRODUCTS. TheStreet Pro Login Subscribe Portfolio (AAP) Latest (All Real Money Pro Authors) Doug's Daily Diary Pro Column: Top Stocks Pro Column: Stocks Under $10 What's New. CATEGORIES.

BOSTON (MarketWatch) -- Johnson & Johnson and Wyeth said Thursday that they were voluntarily pulling several cold medications for babies from shelves, due to reports that some children had been ...

Credit Suisse First Boston maintained a "neutral" rating on Wyeth after the drugmaker announced strong earnings guidance for the third quarter. Wyeth said third-quarter pro forma earnings per ...